Literature DB >> 32865885

AAV Production Everywhere: A Simple, Fast, and Reliable Protocol for In-house AAV Vector Production Based on Chloroform Extraction.

Matilde Negrini1, Gang Wang2, Andreas Heuer1, Tomas Björklund2, Marcus Davidsson2.   

Abstract

Recombinant adeno-associated virus (rAAV) is a mammalian virus that has been altered to be used as a gene delivery vehicle. Several changes to the viral genome have made them replication deficient so that this aspect of the viral infection cycle is under full control of the experimenter, while maintaining gene expression machinery. Over the last decades, rAAVs have become the gold standard for studying in vivo gene function and are especially favorable for gene transfer in the central nervous system. AAVs have been proven safe and provide stable gene expression over a long period of time. They are extensively used in preclinical experiments and show great potential for clinical applications. However, the use of AAVs in preclinical settings are often held back due to availability. Waiting lines are long at commercial production facilities, and in-lab production is hindered due to lack of specific laboratory equipment needed. Here we present a novel production method that can be carried out in any molecular biology laboratory using standard laboratory equipment. We provide a simple, fast, and streamlined protocol for production that can result in titers comparable with the more time-consuming iodixanol gradient ultracentrifugation method. The yield using this protocol is high enough for any type of study where AAV is the vector of choice.
© 2020 The Authors. © 2020 The Authors.

Entities:  

Keywords:  AAV vector; PEI transfection; adeno associated virus; chloroform extraction; gene expression; gene therapy; vector production

Mesh:

Substances:

Year:  2020        PMID: 32865885     DOI: 10.1002/cpns.103

Source DB:  PubMed          Journal:  Curr Protoc Neurosci        ISSN: 1934-8576


  8 in total

1.  Process improvement of adeno-associated virus (AAV) production.

Authors:  Jia-Shiung Guan; Kai Chen; Yingnan Si; Taehyun Kim; Zhuoxin Zhou; Seulhee Kim; Lufang Zhou; Xiaoguang Margaret Liu
Journal:  Front Chem Eng       Date:  2022-01-28

2.  Application of AAV1 for Anterograde Transsynaptic Circuit Mapping and Input-Dependent Neuronal Cataloging.

Authors:  Brian Zingg; Hong-Wei Dong; Huizhong Whit Tao; Li I Zhang
Journal:  Curr Protoc       Date:  2022-01

3.  A comparison of AAV-vector production methods for gene therapy and preclinical assessment.

Authors:  Marcus Davidsson; Matilde Negrini; Swantje Hauser; Alexander Svanbergsson; Marcus Lockowandt; Giuseppe Tomasello; Fredric P Manfredsson; Andreas Heuer
Journal:  Sci Rep       Date:  2020-12-09       Impact factor: 4.379

4.  Targeting Human Osteoarthritic Chondrocytes with Ligand Directed Bacteriophage-Based Particles.

Authors:  Aitthiphon Chongchai; Sajee Waramit; Tunchanok Wongwichai; Jirawan Kampangtip; Thanyaluck Phitak; Prachya Kongtawelert; Amin Hajitou; Keittisak Suwan; Peraphan Pothacharoen
Journal:  Viruses       Date:  2021-11-23       Impact factor: 5.048

5.  A novel two-factor monosynaptic TRIO tracing method for assessment of circuit integration of hESC-derived dopamine transplants.

Authors:  Patrick Aldrin-Kirk; Malin Åkerblom; Tiago Cardoso; Sara Nolbrant; Andrew F Adler; Xiaohe Liu; Andreas Heuer; Marcus Davidsson; Malin Parmar; Tomas Björklund
Journal:  Stem Cell Reports       Date:  2021-12-30       Impact factor: 7.765

6.  A Simplified SARS-CoV-2 Mouse Model Demonstrates Protection by an Oral Replicon-Based mRNA Vaccine.

Authors:  Vijayakumar Jawalagatti; Perumalraja Kirthika; Chamith Hewawaduge; Ji-Young Park; Myeon-Sik Yang; Byungkwan Oh; Mi Young So; Bumseok Kim; John Hwa Lee
Journal:  Front Immunol       Date:  2022-02-16       Impact factor: 7.561

7.  Defunctionalizing intracellular organelles such as mitochondria and peroxisomes with engineered phospholipase A/acyltransferases.

Authors:  Satoshi Watanabe; Yuta Nihongaki; Kie Itoh; Toru Uyama; Satoshi Toda; Shigeki Watanabe; Takanari Inoue
Journal:  Nat Commun       Date:  2022-07-29       Impact factor: 17.694

Review 8.  Next-Generation Gene Therapy for Parkinson's Disease Using Engineered Viral Vectors.

Authors:  Tomas Björklund; Marcus Davidsson
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.